KYMRIAH: payments to doctors
Payments that named KYMRIAH as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.2M
- Providers
- 931
- Transactions
- 2,620
- Average per transaction
- $474
The per-transaction average — $474 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 931 providers the average total is $1,334, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novartis | $1,205,719 | 97.0% |
| Novartis Pharma AG | $36,698 | 3.0% |